Research programme: VEGF receptor kinase inhibitors - Affymax
Latest Information Update: 27 Aug 2009
At a glance
- Originator Affymax
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 May 2005 Preclinical trials in Cancer in USA (unspecified route)